Who is sponsoring NCT03302806?

NCT03302806 is sponsored by Nantes University Hospital.

What drugs are being tested in NCT03302806?

Interventions in NCT03302806: Non interventional Study.

What condition does NCT03302806 study?

NCT03302806 studies Progressive Multiple Sclerosis.

Is NCT03302806 still recruiting?

NCT03302806 is currently completed. Last updated 21 September 2021.

Last reviewed 2021-09-21 · How we verify

NCT03302806: BIOSEP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Assess Effect and Safety of High Dose of Biotin (Qizenday®) in Progressive Multiple Sclerosis

Completed Last updated 21 September 2021

What this trial tests

trial testing Non interventional Study in Progressive Multiple Sclerosis in 103 participants. Completed in 24 October 2018.

Timeline

29 June 2016

Primary endpoint
4 October 2017

24 October 2018

Quick facts

Lead sponsor	Nantes University Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	103
Start date	29 June 2016
Primary completion	4 October 2017
Estimated completion	24 October 2018
Sites	1 location across France

Drugs / interventions tested

Non interventional Study

Conditions studied

Progressive Multiple Sclerosis — all drugs for Progressive Multiple Sclerosis →

Sponsor

Nantes University Hospital

Who can join

18 and older, any sex, with Progressive Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this observational study is to collect efficacy and safety data in real life condition within the first year of treatment in patients with progressive multiple receiving a daily dose of biotine of 300 mg.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Current advancements in promoting remyelination in multiple sclerosis.
Kremer D, Akkermann R, Küry P, Dutta R. · · 2019 · cited 45× · PMID 30270725 · DOI 10.1177/1352458518800827
Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015-2020.
Huntemann N, Rolfes L, Pawlitzki M, Ruck T, et al · · 2021 · cited 30× · PMID 34086251 · DOI 10.1007/s40265-021-01526-w
Oligodendrocyte Development and Regenerative Therapeutics in Multiple Sclerosis.
Gacem N, Nait-Oumesmar B. · · 2021 · cited 15× · PMID 33918664 · DOI 10.3390/life11040327

Verify or expand the search:

Other trials of Non interventional Study

Trials testing the same drug.

NCT02693431 — Impact of Art Therapy on Anxiety Identified During Hospitalizations Among Children With Cystic Fibrosis Aged 8 to 13 · completed

Other recruiting trials for Progressive Multiple Sclerosis

Currently open trials in the same condition.

NCT07282574 — A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrel · Phase 2 · recruiting
NCT07139743 — Obe-cel in Refractory Progressive Forms of Multiple Sclerosis · Phase 1 · recruiting
NCT06675864 — Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 · Phase 1, PHASE2 · recruiting
NCT05811013 — Effects of Transcranial Static Magnetic Field Stimulation (tSMS) in Progressive Multiple Sclerosis · NA · recruiting
NCT05740722 — Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis · Phase 2 · recruiting

Other Nantes University Hospital trials

Trials by the same sponsor.

NCT07278661 — Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery. · Phase 2 · recruiting
NCT06681363 — Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelod · not yet recruiting
NCT07467382 — GOAT (Gait Observation of Achilles Tendon) · not yet recruiting
NCT07490379 — Comparison of the Efficacy of Transcranial Direct Current Stimulation at Home Versus in Hospital Settings in Patients Wi · NA · not yet recruiting
NCT07423481 — Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03302806 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nantes University Hospital
Last refreshed: 21 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03302806.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing